Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Suptavumab

Next Previous
Drug Profile

Suptavumab

Alternative Names: REGN-2222; SAR-438584

Latest Information Update: 17 Aug 2017

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 14 Aug 2017 Discontinued - Phase-III for Respiratory syncytial virus infections (In infants, In neonates, Prevention) in Australia, New Zealand, USA, Bulgaria, Denmark, Finland, Hungary, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, South Africa, Turkey, Canada, Chile, Ukraine, Panama, Germany (IM)
  • 05 May 2017 Regeneron Pharmaceuticals completes enrolment in a phase III trial for Respiratory syncytial virus infections in USA Bulgaria, Denmark, Finland, Hungary, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, Australia, New Zealand, South Africa, Turkey, Canada, Chile, Ukraine, Panama, and Germany
  • 01 Sep 2016 Regeneron Pharmaceuticals completes a phase I trial in Healthy volunteers in USA (IM) (NCT02828397)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top